It’s an indisputable fact that we need better treatments for COVID-19.

This is particularly true in the outpatient setting. Let’s count how many we have today, hmm, this shouldn’t take long. That would be zero — the same number we had over a year ago, when the disease first emerged in China.

Something safe, easy to take as a pill, and inexpensive. Something that isn’t a costly bioengineered molecule that requires lengthy infusions, given within a short time after diagnosis, to a highly contagious person.

Enter ivermectin — and let the controversy begin.

Yes, ivermectin — the drug licensed for use against strongyloides and other parasites, and probably best known to primary providers for its off-label use for scabies and head lice, and for pet owners as a common de-worming agent.

Read More